Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside, the active ingredient in Nipruss, is a vasodilator presented as an injectable solution for intravenous use. It is employed to rapidly lower blood pressure in hypertensive emergencies and to provide controlled hypotension during surgery.

GNH USA supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company follows EU GMP standards and provides full regulatory documentation for global distribution, ensuring product integrity through validated cold‑chain logistics and technical support for healthcare providers.

Sodium nitroprusside is used intravenously to produce rapid vasodilation in several acute cardiovascular conditions.

- Hypertensive emergencies: rapid reduction of arterial pressure to target safe levels. - Controlled hypotension during surgery: maintains a low, stable blood pressure to reduce bleeding. - Acute heart failure: decreases preload and afterload, improving cardiac output and relieving pulmonary congestion.

Sodium nitroprusside may be associated with several adverse reactions, ranging from frequent to rare but serious.

Common Side Effects: - Headache: mild to moderate pain often related to rapid blood pressure changes. - Nausea: transient gastrointestinal discomfort. - Flushing: warmth and redness of the skin. - Hypotension: excessive drop in blood pressure if infusion rate is too high. - Tachycardia: compensatory increase in heart rate. - Dizziness: sensation of light‑headedness during therapy.

Serious or Rare Side Effects: - Cyanide toxicity: accumulation leading to metabolic acidosis and neurologic signs. - Methemoglobinemia: impaired oxygen delivery due to oxidized hemoglobin. - Severe hypotension: refractory low blood pressure requiring emergency intervention. - Cardiac arrhythmias: irregular heart rhythms including ventricular ectopy. - Allergic reactions: rash, pruritus, or anaphylaxis. - Renal impairment: worsening kidney function in susceptible patients.

When using sodium nitroprusside, clinicians should observe several safety measures to minimise risks. - Monitor blood pressure: adjust infusion continuously to avoid excessive hypotension. - Assess cyanide levels: especially during prolonged infusions or high‑dose therapy. - Use cardiac monitoring: watch for tachyarrhythmias or bradycardia. - Avoid in patients with known hypersensitivity to nitroprusside or its components. - Limit duration: keep infusion time as short as clinically feasible. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium nitroprusside can interact with other agents, altering its safety or efficacy profile.

Major Interactions (Avoid): - Concurrent potent vasodilators: may cause profound hypotension. - Monoamine oxidase (MAO) inhibitors: can potentiate vasodilatory response. - Other cyanide‑producing drugs (e.g., nitroglycerin): increase risk of cyanide accumulation.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance preload reduction and hypotension. - Beta‑blockers: may mask tachycardia that signals excessive blood pressure fall. - ACE inhibitors or ARBs: additive blood pressure‑lowering effect. - Calcium channel blockers: may increase vasodilatory effect.